Cover Image
市場調查報告書

南美錐蟲病:開發中產品分析

Chagas Disease - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 268985
出版日期 內容資訊 英文 83 Pages
訂單完成後即時交付
價格
Back to Top
南美錐蟲病:開發中產品分析 Chagas Disease - Pipeline Review, H1 2017
出版日期: 2017年05月16日 內容資訊: 英文 83 Pages
簡介

所謂南美錐蟲病是由於枯氏錐蟲這個寄生原蟲而發病,是節肢動物媒介性的人畜共通感染疾病。主要的症狀是感染處腫脹和發熱、倦怠感、身體疼痛、食慾不振、噁心與嘔吐、腹瀉、腺腫脹等。主要的治療方法有抗寄生蟲藥物療法等

本報告提供全球各國治療南美錐蟲病所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

南美錐蟲病的概要

治療藥的開發

  • 開發中產品的概要
  • 各企業的開發中產品
  • 各大學/研究機關的開發中產品
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

南美錐蟲病的治療藥開發企業

  • AstraZeneca Plc
  • Bayer AG
  • 第一三共
  • Eisai
  • GlaxoSmithKline Plc
  • Grupo Praxis Pharmaceutical SA
  • KaloBios Pharmaceuticals Inc
  • Kancera AB
  • Novartis AG
  • Oblita Therapeutics BVBA
  • Sanofi

藥物簡介

南美錐蟲病:暫停中的計劃

南美錐蟲病:開發中止的產品

南美錐蟲病:產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9253IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides an overview of the Chagas Disease (Infectious Disease) pipeline landscape.

Chagas disease or American Trypanosomiasis is a vector-borne anthropozoonosis caused by the protozoan parasite Trypanosoma cruzi. Symptoms include swelling at the infection site, fever, fatigue, body aches, loss of appetite, nausea, diarrhea or vomiting and swollen glands. Treatment includes antiparasitic medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chagas Disease (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chagas Disease (American Trypanosomiasis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 3, 4 and 6 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 17 and 4 molecules, respectively.

Chagas Disease (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chagas Disease (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Chagas Disease (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chagas Disease (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chagas Disease (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chagas Disease (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chagas Disease (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chagas Disease (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Chagas Disease (American Trypanosomiasis) - Overview
    • Chagas Disease (American Trypanosomiasis) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Chagas Disease (American Trypanosomiasis) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Chagas Disease (American Trypanosomiasis) - Companies Involved in Therapeutics Development
    • AstraZeneca Plc
    • Bayer AG
    • Daiichi Sankyo Company Ltd
    • Eisai Co Ltd
    • GlaxoSmithKline Plc
    • Grupo Praxis Pharmaceutical SA
    • KaloBios Pharmaceuticals Inc
    • Kancera AB
    • Novartis AG
    • Oblita Therapeutics BVBA
    • Sanofi
  • Chagas Disease (American Trypanosomiasis) - Drug Profiles
    • benznidazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • benznidazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • chagas disease (bivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • chagas disease vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • chagas disease vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Chagas disease vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cz-007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cz-008 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • D-121 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EPLBS-1246 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EPLBS-967 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fexinidazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fosravuconazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GNF-6702 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • K-777 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KAN-0441411 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MAO-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NEU-321 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nifurtimox - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nifurtimox SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAR-114137 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Chagas Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Cruzipain for Chagas Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit SOD for Chagas Disease and Leishmaniasis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Chagas Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Chagas Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Chagas Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Chagas Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Infectious Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Infectious Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Leishmaniasis and Chagas Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Cruzipain for Chagas Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Lanosterol 14 alpha-Demethylase for Chagas Disease, Leishmaniasis and African Trypanosomiasis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Proline Racemase for Chagas Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VNI - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Chagas Disease (American Trypanosomiasis) - Dormant Projects
  • Chagas Disease (American Trypanosomiasis) - Discontinued Products
  • Chagas Disease (American Trypanosomiasis) - Product Development Milestones
    • Featured News & Press Releases
      • Apr 06, 2017: Benznidazole on Track in Progress to IND and NDA Submissions
      • Jan 05, 2017: KaloBios Announces Positive Guidance from FDA for Benznidazole
      • Dec 12, 2016: KaloBios Completes Meeting with FDA for Benznidazole
      • Nov 15, 2016: Bayer to Fight Chagas Disease in Children
      • Aug 08, 2016: A single compound could treat three parasitic diseases
      • Apr 11, 2016: KaloBios Announces New Product Pricing Model
      • Jul 27, 2015: NIH helps UC San Diego researchers repurpose Sanofi pain drug for tropical disease
      • May 07, 2015: UTMB researchers devise vaccine that provides long-term protection against Chagas disease
      • Dec 26, 2013: New Drug Candidates Show Promise for Cure for Chagas Disease
      • Nov 14, 2013: Drug Trial for Leading Parasitic Killer of the Americas Shows Mixed Results but Provides New Evidence for Improved Therapy
      • May 03, 2013: Funding boost for GSK's open innovation research into diseases affecting the developing world
      • Apr 30, 2012: NYU School of Medicine Receives Support From The Tres Cantos Open Lab Foundation To Discover New Drugs Against Chagas Disease
      • Mar 12, 2012: DNDi Receives €2m Strategic Translation Award From Wellcome Trust To Develop New Drug Against Chagas Disease
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Chagas Disease (American Trypanosomiasis), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Chagas Disease (American Trypanosomiasis) - Pipeline by AstraZeneca Plc, H1 2017
  • Chagas Disease (American Trypanosomiasis) - Pipeline by Bayer AG, H1 2017
  • Chagas Disease (American Trypanosomiasis) - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
  • Chagas Disease (American Trypanosomiasis) - Pipeline by Eisai Co Ltd, H1 2017
  • Chagas Disease (American Trypanosomiasis) - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Chagas Disease (American Trypanosomiasis) - Pipeline by Grupo Praxis Pharmaceutical SA, H1 2017
  • Chagas Disease (American Trypanosomiasis) - Pipeline by KaloBios Pharmaceuticals Inc, H1 2017
  • Chagas Disease (American Trypanosomiasis) - Pipeline by Kancera AB, H1 2017
  • Chagas Disease (American Trypanosomiasis) - Pipeline by Novartis AG, H1 2017
  • Chagas Disease (American Trypanosomiasis) - Pipeline by Oblita Therapeutics BVBA, H1 2017
  • Chagas Disease (American Trypanosomiasis) - Pipeline by Sanofi, H1 2017
  • Chagas Disease (American Trypanosomiasis) - Dormant Projects, H1 2017
  • Chagas Disease (American Trypanosomiasis) - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Chagas Disease (American Trypanosomiasis), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top